HRP20160857T4 - Bispecifična jednolančana protutijela, specifična za visokomolekulske ciljne antigene - Google Patents
Bispecifična jednolančana protutijela, specifična za visokomolekulske ciljne antigene Download PDFInfo
- Publication number
- HRP20160857T4 HRP20160857T4 HRP20160857TT HRP20160857T HRP20160857T4 HR P20160857 T4 HRP20160857 T4 HR P20160857T4 HR P20160857T T HRP20160857T T HR P20160857TT HR P20160857 T HRP20160857 T HR P20160857T HR P20160857 T4 HRP20160857 T4 HR P20160857T4
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- cdr
- domain
- extracellular domain
- cell surface
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims 27
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 9
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 9
- 102100038083 Endosialin Human genes 0.000 claims 7
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 7
- 102000014429 Insulin-like growth factor Human genes 0.000 claims 7
- 125000000539 amino acid group Chemical group 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 101000884275 Homo sapiens Endosialin Proteins 0.000 claims 6
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims 5
- 108010072257 fibroblast activation protein alpha Proteins 0.000 claims 5
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 4
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 4
- 241000283984 Rodentia Species 0.000 claims 3
- 230000009089 cytolysis Effects 0.000 claims 3
- 210000003162 effector t lymphocyte Anatomy 0.000 claims 3
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 claims 2
- 241001529936 Murinae Species 0.000 claims 2
- 241000288950 Callithrix jacchus Species 0.000 claims 1
- 102000012545 EGF-like domains Human genes 0.000 claims 1
- 108050002150 EGF-like domains Proteins 0.000 claims 1
- 101710144543 Endosialin Proteins 0.000 claims 1
- 102000002090 Fibronectin type III Human genes 0.000 claims 1
- 108050009401 Fibronectin type III Proteins 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims 1
- 101000684220 Mus musculus Prolyl endopeptidase FAP Proteins 0.000 claims 1
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 claims 1
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 claims 1
- 241000288960 Saguinus oedipus Species 0.000 claims 1
- 241000282696 Saimiri sciureus Species 0.000 claims 1
- 102000009203 Sema domains Human genes 0.000 claims 1
- 108050000099 Sema domains Proteins 0.000 claims 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Claims (7)
1. Postupak odabiranja bispecifičnih jednolančanih protutijela, koja sadrže prvu vežuću domenu, koja se može vezati na epitop CD3, i drugu vežuću domenu, koja se može vezati na izvanstaničnu domenu membranskog antigena specifičnog za prostatu (PSMA), naznačen time što se sastoji u koracima:
(a) osiguravanja najmanje tri tipa stanica domaćina koje eksprimiraju
(i) wt ljudsku izvanstaničnu domenu PSMA sa SEQ ID:447 na površini stanice;
(ii) mutirani oblik wt ljudskog PSMA na površini stanice, gdje su aminokiselinski ostaci na položajima 140, 169, 191, 308, 334, 339, 344, 624, 626, 716, 717 i 721 mutirani u odgovarajuće aminokiselinske ostatke wt štakorskog PSMA; i
(iii) štakorsku wt izvanstaničnu domenu PSMA na površini stanice;
(b) stavljanja u kontakt svakog tipa stanica domaćina (i), (ii) i (iii) u koraku (a) s bispecifičnim jednolančanim protutijelima i efektorskim T-stanicama; i
(c) identificiranja i izdvajanja bispecifičnih jednolančanih protutijela koja posreduju kod lize stanica domaćina koje eksprimiraju wt ljudsku izvanstaničnu domenu PSMA na površini stanice u skladu s (b)(i) i stanica domaćina koje eksprimiraju mutirani oblik wt ljudskog PSMA na površini stanice u skladu s (b)(ii), no ne i stanica domaćina koje eksprimiraju štakorsku wt izvanstaničnu domenu PSMA na površini stanice u skladu s b(iii).
2. Postupak odabiranja bispecifičnih jednolančanih protutijela, koja sadrže prvu vežuću domenu, koja se može vezati na epitop CD3, i drugu vežuću domenu, koja se može vezati na izvanstaničnu domenu fibroblast-aktivirajućeg proteina α (FAPα), naznačen time što se sastoji u koracima:
(a) osiguravanja najmanje tri tipa stanica domaćina koje eksprimiraju
(i) wt ljudsku izvanstaničnu domenu FAPα sa SEQ ID:448 na površini stanice;
(ii) mutirani oblik wt ljudskog FAPα na površini stanice, gdje su aminokiselinski ostaci na položajima 144, 185, 186, 229, 267, 273, 274, 278, 284, 301, 328, 329, 331, 335 i 362 mutirani u odgovarajuće aminokiselinske ostatke wt mišjeg FAPα; i
(iii) mišju wt izvanstaničnu domenu FAPα na površini stanice;
(b) stavljanja u kontakt svakog tipa stanica domaćina (i), (ii) i (iii) u koraku (a) s bispecifičnim jednolančanim protutijelima i efektorskim T-stanicama; i
(c) identificiranja i izdvajanja bispecifičnih jednolančanih protutijela koja posreduju kod lize stanica domaćina koje eksprimiraju wt ljudsku izvanstaničnu domenu FAPα na površini stanice u skladu s (b)(i) i stanica domaćina koje eksprimiraju mutirani oblik wt ljudskog FAPα na površini stanice u skladu s (b)(ii), no ne i stanica domaćina koje eksprimiraju mišju wt izvanstaničnu domenu FAPα na površini stanice u skladu s b(iii).
3. Postupak odabiranja bispecifičnih jednolančanih protutijela, koja sadrže prvu vežuću domenu, koja se može vezati na epitop CD3, i drugu vežuću domenu, koja se može vezati na izvanstaničnu domenu receptora čimbenika rasta hepatocita (c-MET), endosijalina (TEM1) i tip 1 receptora inzulinu sličnog čimbenika rasta (IGF-1R), naznačen time što se sastoji u koracima:
(a) identificiranja membranskih proksimalnih 640 aminokiselinskih ostataka u ljudskom i glodavačkom homologu izvanstanične domene c-MET, TEM1 ili IGF-1R;
(b) osiguravanja stanica domaćina koje eksprimiraju
(i) ljudske wt izvanstanične domene izvanstanične domene c-MET, TEM1 ili IGF-1R na površini stanice;
(ii) fuzijski protein koji sadrži ljudske membranske proksimalne 640 aminokiselinskih ostataka identificiranih u koraku (a) i glodavačke aminokiselinske ostatke >640 u c-MET, TEM1 ili IGF-1R; i
(iii) glodavačku wt izvanstaničnu domenu c-MET, TEM1 ili IGF-1R;
(c) stavljanja u kontakt stanica domaćina u skladu s korakom (b) s bispecifičnim jednolančanim protutijelima i efektorskim T-stanicama; i
(d) identificiranja i izdvajanja bispecifičnih jednolančanih protutijela koja posreduju kod lize stanica domaćina u skladu s (b)(i) i (b)(ii), no ne i stanica domaćina u skladu s b(iii).
4. Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što prva vežuća domena se veže na CD3 epsilon (CD3ε) kod čovjeka, te Callithrix jacchus, Saguinus oedipus ili Saimiri sciureus.
5. Postupak u skladu s patentnim zahtjevom 4, naznačen time što prva vežuća domena sadrži područje VL koje sadrži CDR-L1, CDR-L2 i CDR-L3, koje se bira između:
(a) CDR-L1, kao što je opisano u SEQ ID NO. 27, CDR-L2, kao što je opisano u SEQ ID NO. 28 i CDR-L3, kao što je opisano u SEQ ID NO. 29;
(b) CDR-L1, kao što je opisano u SEQ ID NO. 117, CDR-L2, kao što je opisano u SEQ ID NO. 118 i CDR-L3, kao što je opisano u SEQ ID NO. 119; i
(c) CDR-L1, kao što je opisano u SEQ ID NO. 153, CDR-L2, kao što je opisano u SEQ ID NO. 154 i CDR-L3, kao što je opisano u SEQ ID NO. 155.
6. Postupak u skladu s patentnim zahtjevom 4, naznačen time što prva vežuća domena sadrži područje VH koje sadrži CDR-H 1, CDR-H2 i CDR-H3, koje se bira između:
(a) CDR-H1, kao što je opisano u SEQ ID NO. 12, CDR-H2, kao što je opisano u SEQ ID NO. 13 i CDR-H3, kao što je opisano u SEQ ID NO. 14;
(b) CDR-H1, kao što je opisano u SEQ ID NO. 30, CDR-H2, kao što je opisano u SEQ ID NO. 31 i CDR-H3, kao što je opisano u SEQ ID NO. 32;
(c) CDR-H1, kao što je opisano u SEQ ID NO. 48, CDR-H2, kao što je opisano u SEQ ID NO. 49 i CDR-H3, kao što je opisano u SEQ ID NO. 50;
(d) CDR-H1, kao što je opisano u SEQ ID NO. 66, CDR-H2, kao što je opisano u SEQ ID NO. 67 i CDR-H3, kao što je opisano u SEQ ID NO. 68;
(e) CDR-H1, kao što je opisano u SEQ ID NO. 84, CDR-H2, kao što je opisano u SEQ ID NO. 85 i CDR-H3, kao što je opisano u SEQ ID NO. 86;
(f) CDR-H1, kao što je opisano u SEQ ID NO. 102, CDR-H2, kao što je opisano u SEQ ID NO. 103 i CDR-H3, kao što je opisano u SEQ ID NO. 104;
(g) CDR-H1, kao što je opisano u SEQ ID NO. 120, CDR-H2, kao što je opisano u SEQ ID NO. 121 i CDR-H3, kao što je opisano u SEQ ID NO. 122;
(h) CDR-H1, kao što je opisano u SEQ ID NO. 138, CDR-H2, kao što je opisano u SEQ ID NO. 139 i CDR-H3, kao što je opisano u SEQ ID NO. 140;
(i) CDR-H1, kao što je opisano u SEQ ID NO. 156, CDR-H2, kao što je opisano u SEQ ID NO. 157 i CDR-H3, kao što je opisano u SEQ ID NO. 158; i
(j) CDR-H1, kao što je opisano u SEQ ID NO. 174, CDR-H2, kao što je opisano u SEQ ID NO. 175 i CDR-H3, kao što je opisano u SEQ ID NO. 176.
7. Postupak u skladu s bilo kojim od patentnih zahtjeva 3 do 6, naznačen time što se druga vežuća domena veže na epitope/vežuća mjesta koja se bira iz skupine koju čine:
epitopi/vežuća mjesta u četiri Ig domene sa SEQ ID:436, cisteinom bogata domena sa SEQ ID:437 ili beta-lanac sema domene sa SEQ ID:438 izvanstanične domene c-MET,
epitopi/vežuća mjesta u mucinskoj domeni sa SEQ ID:440, tri EGF-u slične domene sa SEQ ID:441 ili Sushi/SCR/CCP domena sa SEQ ID:442 izvanstanične domene TEM1,
i
epitopi/vežuća mjesta u tri fibronektin tip III domene sa SEQ ID:444 i L2 domeni sa SEQ ID:445 izvanstanične domene IGF-1R.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10193308P | 2008-10-01 | 2008-10-01 | |
| PCT/EP2009/062794 WO2010037837A2 (en) | 2008-10-01 | 2009-10-01 | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
| EP09736398.0A EP2352763B2 (en) | 2008-10-01 | 2009-10-01 | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20160857T1 HRP20160857T1 (hr) | 2016-10-21 |
| HRP20160857T4 true HRP20160857T4 (hr) | 2022-12-09 |
Family
ID=42073957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160857TT HRP20160857T4 (hr) | 2008-10-01 | 2009-10-01 | Bispecifična jednolančana protutijela, specifična za visokomolekulske ciljne antigene |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US9260522B2 (hr) |
| EP (1) | EP2352763B2 (hr) |
| AU (1) | AU2009299793B2 (hr) |
| CA (1) | CA2738566A1 (hr) |
| CY (1) | CY1117718T1 (hr) |
| DK (1) | DK2352763T4 (hr) |
| ES (1) | ES2582603T5 (hr) |
| HR (1) | HRP20160857T4 (hr) |
| HU (1) | HUE027499T2 (hr) |
| PL (1) | PL2352763T5 (hr) |
| PT (1) | PT2352763E (hr) |
| SI (1) | SI2352763T2 (hr) |
| SM (1) | SMT201600232B (hr) |
| WO (1) | WO2010037837A2 (hr) |
Families Citing this family (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE030090T2 (en) * | 2008-10-01 | 2017-04-28 | Amgen Res (Munich) Gmbh | Species specific PSMAxCD3 bispecific single chain antibody |
| PT3330293T (pt) * | 2008-11-07 | 2019-10-18 | Amgen Res Munich Gmbh | Tratamento da leucemia linfoblástica aguda pediátrica com anticorpos biespecíficos contra cd3xcd19 |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| TWI653333B (zh) * | 2010-04-01 | 2019-03-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體 |
| EP2400298B1 (en) * | 2010-05-28 | 2013-08-14 | F.Hoffmann-La Roche Ag | Single B-cell cultivation method and specific antibody production |
| EP3029066B1 (en) | 2010-07-29 | 2019-02-20 | Xencor, Inc. | Antibodies with modified isoelectric points |
| UA114077C2 (xx) * | 2010-11-19 | 2017-04-25 | Нейтралізуюче антитіло проти ccl20 | |
| CN103561771B (zh) | 2011-03-17 | 2019-01-04 | 伯明翰大学 | 重新定向的免疫治疗 |
| CN103687872A (zh) | 2011-04-22 | 2014-03-26 | 新兴产品开发西雅图有限公司 | 前列腺特异性膜抗原结合蛋白和相关组合物以及方法 |
| KR20130036993A (ko) | 2011-10-05 | 2013-04-15 | 삼성전자주식회사 | ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체 |
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| EP2791338B1 (en) * | 2011-12-15 | 2019-02-20 | The Royal Institution for the Advancement of Learning / McGill University | Soluble igf receptor fc fusion proteins and uses thereof |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
| WO2014023315A1 (en) | 2012-08-10 | 2014-02-13 | Aarhus Universitet | Multimerization through beta-strand swapping in ccp domains |
| EP2708556B1 (en) | 2012-09-12 | 2018-11-07 | Samsung Electronics Co., Ltd | Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases |
| RU2679124C2 (ru) * | 2012-11-06 | 2019-02-06 | Байер Фарма Акциенгезельшафт | Препарат для биспецифических активаторов т-клеток (bite) |
| US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
| US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| AU2014205086B2 (en) | 2013-01-14 | 2019-04-18 | Xencor, Inc. | Novel heterodimeric proteins |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| WO2014113510A1 (en) | 2013-01-15 | 2014-07-24 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
| EP2762497A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| ES2829499T3 (es) | 2013-02-05 | 2021-06-01 | Engmab Sarl | Método para la selección de anticuerpos contra BCMA |
| EP2762496A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Method for the selection of antibodies against BCMA |
| US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
| CA2906927C (en) | 2013-03-15 | 2021-07-13 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| US20140302037A1 (en) * | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
| EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| EP3092491B1 (en) * | 2014-01-07 | 2018-10-31 | Bioatla, LLC | Proteins targeting orthologs |
| US9822186B2 (en) | 2014-03-28 | 2017-11-21 | Xencor, Inc. | Bispecific antibodies that bind to CD38 and CD3 |
| US9884921B2 (en) | 2014-07-01 | 2018-02-06 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
| US9212225B1 (en) | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| MA41019A (fr) | 2014-11-26 | 2021-05-05 | Xencor Inc | Anticorps hétérodimériques se liant aux antigènes cd3 et cd38 |
| MA55043A (fr) | 2014-11-26 | 2021-12-29 | Xencor Inc | Anticorps hétérodimériques se liant à l'antigène cd3 et l'antigène cd20 |
| EP3237449A2 (en) | 2014-12-22 | 2017-11-01 | Xencor, Inc. | Trispecific antibodies |
| CA2971288A1 (en) | 2015-02-02 | 2016-08-11 | The University Of Birmingham | Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes |
| WO2016138071A1 (en) | 2015-02-24 | 2016-09-01 | Short Jay M | Conditionally active biological proteins |
| WO2016141387A1 (en) | 2015-03-05 | 2016-09-09 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| MA42059A (fr) | 2015-05-06 | 2018-03-14 | Janssen Biotech Inc | Agents de liaison bispécifique à l'antigène membranaire spécifique de la prostate (psma) et utilisations de ceux-ci |
| ES2889906T3 (es) | 2015-05-21 | 2022-01-14 | Harpoon Therapeutics Inc | Proteínas de unión triespecíficas y usos médicos |
| EA201792581A1 (ru) | 2015-05-29 | 2018-07-31 | Амфивена Терапьютикс, Инк. | Способы применения биспецифических cd33- и cd3- связывающих белков |
| DK3328414T3 (da) | 2015-07-31 | 2020-08-31 | Blue Blood Biotech Corp | Sammensætning til anvendelse i fremme af sårheling |
| EA036975B1 (ru) | 2015-08-03 | 2021-01-21 | Энгмаб Сарл | Моноклональные антитела против bcma |
| ES2814550T3 (es) | 2015-08-17 | 2021-03-29 | Janssen Pharmaceutica Nv | Anticuerpos anti-BCMA, moléculas que se unen a antígeno biespecífico que se unen a BCMA y CD3, y usos de los mismos |
| EA038329B1 (ru) | 2015-08-28 | 2021-08-10 | Амьюникс Фармасьютикалз, Инк. | Химерный полипептидный комплекс и способы его получения и применения |
| BR112018005573A2 (pt) | 2015-09-21 | 2019-01-22 | Aptevo Research And Development Llc | ?polipeptídeos de ligação a cd3? |
| EA201891084A1 (ru) | 2015-11-02 | 2019-10-31 | Антитела к il1rap, биспецифические антигенсвязывающие молекулы, которые связываются с il1rap и cd3, и их применение | |
| WO2017087547A1 (en) * | 2015-11-17 | 2017-05-26 | Oncomed Pharmaceuticals, Inc. | Pd-l1-binding agents and uses thereof |
| CN108289952B (zh) | 2015-11-19 | 2021-02-05 | 雷维托普有限公司 | 用于对非所要细胞进行重定向杀灭的两组分系统的功能性抗体片段互补作用 |
| EP3387013B1 (en) | 2015-12-07 | 2022-06-08 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and psma |
| EP3192810A1 (en) | 2016-01-14 | 2017-07-19 | Deutsches Krebsforschungszentrum | Psma binding antibody and uses thereof |
| SG11201807336RA (en) * | 2016-03-16 | 2018-09-27 | Univ California | Protein a binding polypeptides, anti-epha2 antibodies and methods of use thereof |
| CN109641047A (zh) | 2016-05-20 | 2019-04-16 | 哈普恩治疗公司 | 单结构域血清白蛋白结合蛋白质 |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| SG11201810331YA (en) * | 2016-05-20 | 2018-12-28 | Harpoon Therapeutics Inc | Single chain variable fragment cd3 binding proteins |
| KR102523402B1 (ko) | 2016-06-14 | 2023-04-19 | 젠코어 인코포레이티드 | 이중특이적 체크포인트 억제제 항체 |
| US11613572B2 (en) | 2016-06-21 | 2023-03-28 | Teneobio, Inc. | CD3 binding antibodies |
| JP7021127B2 (ja) | 2016-06-28 | 2022-02-16 | ゼンコア インコーポレイテッド | ソマトスタチン受容体２に結合するヘテロ二量体抗体 |
| TWI781108B (zh) | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| CN114395048A (zh) | 2016-09-14 | 2022-04-26 | 特尼奥生物股份有限公司 | Cd3结合抗体 |
| SG11201903302UA (en) | 2016-10-14 | 2019-05-30 | Xencor Inc | Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments |
| BR112019008426A2 (pt) | 2016-11-02 | 2019-09-03 | Engmab Sarl | anticorpo biespecífico contra bcma e cd3 e um fármaco imunológico para uso combinado no tratamento de mieloma múltiplo |
| MX2019006045A (es) * | 2016-11-23 | 2019-11-11 | Harpoon Therapeutics Inc | Proteinas triespecificas dirigidas a psma y metodos de uso. |
| EP3544997A4 (en) | 2016-11-23 | 2020-07-01 | Harpoon Therapeutics, Inc. | PROSTATE SPECIFIC MEMBRANE ANTIGEN BINDING PROTEIN |
| KR102633423B1 (ko) | 2016-12-21 | 2024-02-06 | 테네오바이오, 인코포레이티드 | 항-bcma 중쇄-단독 항체 |
| WO2018140845A2 (en) * | 2017-01-27 | 2018-08-02 | Duke University | Bi-specific antibodies to cd64 and a disease antigen |
| US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| CA3063362A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Msln targeting trispecific proteins and methods of use |
| JP7090347B2 (ja) | 2017-05-12 | 2022-06-24 | ハープーン セラピューティクス，インク． | メソテリン結合タンパク質 |
| WO2019006472A1 (en) | 2017-06-30 | 2019-01-03 | Xencor, Inc. | TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS |
| BR112020002636A2 (pt) | 2017-08-10 | 2020-07-28 | Grifols Diagnostic Solutions Inc. | composições, métodos e/ou kits que compreendem um domínio extracelular recombinante de cd38 humano |
| KR102390770B1 (ko) * | 2017-09-29 | 2022-04-25 | 세키스이 메디칼 가부시키가이샤 | 라텍스 면역 응집법에 있어서의 측정 오차 저감 방법 |
| KR102569133B1 (ko) | 2017-10-13 | 2023-08-21 | 하푼 테라퓨틱스, 인크. | 삼중특이적 단백질 및 사용 방법 |
| CR20200195A (es) | 2017-10-13 | 2020-08-14 | Harpoon Therapeutics Inc | Proteínas de unión a antigenos de maduraciòn de celulas b |
| CA3082383A1 (en) | 2017-11-08 | 2019-05-16 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-pd-1 sequences |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| JP2021506291A (ja) | 2017-12-19 | 2021-02-22 | ゼンコア インコーポレイテッド | 改変されたｉｌ−２ ｆｃ融合タンパク質 |
| JP2021514658A (ja) * | 2018-03-06 | 2021-06-17 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 前立腺特異的膜抗原ｃａｒおよびその使用方法 |
| CA3096052A1 (en) | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| CN112437777A (zh) | 2018-04-18 | 2021-03-02 | Xencor股份有限公司 | 包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白 |
| US11524991B2 (en) | 2018-04-18 | 2022-12-13 | Xencor, Inc. | PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof |
| JOP20190116A1 (ar) | 2018-05-24 | 2019-11-24 | Janssen Biotech Inc | الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها |
| CA3098420A1 (en) | 2018-06-01 | 2019-12-05 | Novartis Ag | Binding molecules against bcma and uses thereof |
| US20210221908A1 (en) | 2018-06-03 | 2021-07-22 | Lamkap Bio Beta Ltd. | Bispecific antibodies against ceacam5 and cd47 |
| SG11202012342WA (en) * | 2018-06-18 | 2021-01-28 | Eureka Therapeutics Inc | Constructs targeting prostate-specific membrane antigen (psma) and uses thereof |
| CN113286817A (zh) | 2018-09-25 | 2021-08-20 | 哈普恩治疗公司 | Dll3结合蛋白及使用方法 |
| CN113195523A (zh) | 2018-10-03 | 2021-07-30 | Xencor股份有限公司 | IL-12异源二聚体Fc融合蛋白 |
| KR20210100654A (ko) * | 2018-12-07 | 2021-08-17 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | Cd3 항체 및 그의 약제학적 용도 |
| CN114173875A (zh) | 2019-03-01 | 2022-03-11 | Xencor股份有限公司 | 结合enpp3和cd3的异二聚抗体 |
| EP3966250A4 (en) * | 2019-05-07 | 2022-11-23 | Immunorizon Ltd. | PRECURSOR TRI-SPECIFIC ANTIBODY CONSTRUCTIONS AND METHODS OF USE THEREOF |
| GB201906685D0 (en) * | 2019-05-13 | 2019-06-26 | Ultrahuman Six Ltd | Activatable protein constructs and uses thereof |
| KR20220020810A (ko) | 2019-06-14 | 2022-02-21 | 테네오바이오, 인코포레이티드 | Cd22와 cd3에 결합하는 다중특이적 중쇄 항체 |
| CA3150265A1 (en) | 2019-09-18 | 2021-03-25 | Sara MAJOCCHI | BISPECIFIC ANTIBODIES DIRECTED AGAINST CEACAM5 AND CD3 |
| EP3831849A1 (en) | 2019-12-02 | 2021-06-09 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
| US20230075633A1 (en) * | 2019-12-20 | 2023-03-09 | Shandong Boan Biotechnology Co., Ltd. | Optimized anti-cd3 arm in the generation of t-cell bispecific antibodies for immunotherapy |
| CN115768463A (zh) | 2020-02-21 | 2023-03-07 | 哈普恩治疗公司 | Flt3结合蛋白及使用方法 |
| PE20230431A1 (es) | 2020-04-29 | 2023-03-08 | Teneobio Inc | Anticuerpos de cadena pesada multiespecificos con regiones constantes de cadena pesada modificadas |
| KR20230009450A (ko) | 2020-05-11 | 2023-01-17 | 얀센 바이오테크 인코포레이티드 | 다발성 골수종을 치료하기 위한 방법 |
| US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
| IL300666A (en) | 2020-08-19 | 2023-04-01 | Xencor Inc | ANTI–CD28 COMPOSITIONS |
| EP4259193A1 (en) | 2020-12-09 | 2023-10-18 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
| IL305144A (en) | 2021-02-16 | 2023-10-01 | Janssen Pharmaceutica Nv | Trispecific antibodies targeting BCMA, GPRC5D and CD3 |
| EP4305067A1 (en) | 2021-03-09 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
| WO2022192586A1 (en) | 2021-03-10 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
| JP2024511115A (ja) | 2021-03-24 | 2024-03-12 | ヤンセン バイオテツク，インコーポレーテツド | ＣＤ７９ｂ、ＣＤ２０、及びＣＤ３を標的とする三重特異性抗体 |
| WO2023039242A2 (en) * | 2021-09-13 | 2023-03-16 | Achelois Biopharma, Inc. | Multivalent interferon particles compositions and methods of use |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| TR200003087T2 (tr) | 1998-04-21 | 2001-02-21 | Micromet Ag | Yeni CD19 X CD3 Spesifik polipeptidler ve kullanımları |
| EP1293514B1 (en) | 2001-09-14 | 2006-11-29 | Affimed Therapeutics AG | Multimeric single chain tandem Fv-antibodies |
| EP1448588A4 (en) * | 2001-10-23 | 2006-10-25 | Psma Dev Company L L C | ANTIBODIES AND MULTIMERS OF PSMA PROTEINS |
| RU2005141512A (ru) * | 2003-05-31 | 2007-07-20 | Микромет Аг (De) | Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками |
| US8784821B1 (en) † | 2003-05-31 | 2014-07-22 | Amgen Research (Munich) Gmbh | Human-anti-human cd3 binding molecules |
| BRPI0415457A (pt) † | 2003-10-16 | 2006-12-05 | Micromet Ag | constructo de ligação especìfico de cd3 citotoxicamente ativo, seu processo de produção, composição compreendendo o mesmo, seqüência de ácido nucléico, vetor, hospedeiro, seus usos na preparação de uma composição farmacêutica e kit compreendendo os mesmo |
| PT1851250E (pt) † | 2005-02-18 | 2012-08-27 | Medarex Inc | Anticorpo monoclonal humano para o antigénio membranar específico da próstata (psma) |
| EP1726650A1 (en) * | 2005-05-27 | 2006-11-29 | Universitätsklinikum Freiburg | Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen |
| JP5686953B2 (ja) * | 2005-10-11 | 2015-03-18 | アムゲン リサーチ （ミュンヘン） ゲーエムベーハー | 交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用 |
| WO2008119566A2 (en) † | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific bispecific binders |
| BRPI0809594A2 (pt) * | 2007-04-03 | 2019-08-27 | Micromet Ag | polipeptídeo, seqüência de ácido nucléico, vetor, hospedeiro, processo para a produção de um polipeptídeo, composição farmacêutica, uso de um polipeptídeo, método para prevenção, tratamento ou melhora de uma doença, em um indivíduo com necessidade do mesmo, kit, método para a identificação de um polipeptídeo(s) |
| PL2520590T3 (pl) | 2007-04-03 | 2019-02-28 | Amgen Research (Munich) Gmbh | Domena wiążąca wykazująca krzyżową swoistość gatunkową |
| TWI653333B (zh) * | 2010-04-01 | 2019-03-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體 |
-
2009
- 2009-10-01 DK DK09736398.0T patent/DK2352763T4/da active
- 2009-10-01 WO PCT/EP2009/062794 patent/WO2010037837A2/en active Application Filing
- 2009-10-01 PT PT09736398T patent/PT2352763E/pt unknown
- 2009-10-01 AU AU2009299793A patent/AU2009299793B2/en active Active
- 2009-10-01 EP EP09736398.0A patent/EP2352763B2/en active Active
- 2009-10-01 ES ES09736398T patent/ES2582603T5/es active Active
- 2009-10-01 SI SI200931442T patent/SI2352763T2/sl unknown
- 2009-10-01 HR HRP20160857TT patent/HRP20160857T4/hr unknown
- 2009-10-01 US US13/122,271 patent/US9260522B2/en active Active
- 2009-10-01 PL PL09736398.0T patent/PL2352763T5/pl unknown
- 2009-10-01 HU HUE09736398A patent/HUE027499T2/en unknown
- 2009-10-01 CA CA2738566A patent/CA2738566A1/en active Granted
-
2016
- 2016-01-08 US US14/991,189 patent/US10047159B2/en active Active
- 2016-07-04 CY CY20161100616T patent/CY1117718T1/el unknown
- 2016-07-14 SM SM201600232T patent/SMT201600232B/it unknown
-
2018
- 2018-07-12 US US16/034,134 patent/US20190040133A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20160857T1 (hr) | 2016-10-21 |
| EP2352763B1 (en) | 2016-04-13 |
| EP2352763A2 (en) | 2011-08-10 |
| ES2582603T3 (es) | 2016-09-14 |
| AU2009299793A1 (en) | 2010-04-08 |
| US10047159B2 (en) | 2018-08-14 |
| US20190040133A1 (en) | 2019-02-07 |
| WO2010037837A2 (en) | 2010-04-08 |
| EP2352763B2 (en) | 2022-09-21 |
| CY1117718T1 (el) | 2017-05-17 |
| DK2352763T4 (da) | 2022-10-17 |
| PT2352763E (pt) | 2016-06-02 |
| PL2352763T5 (pl) | 2023-01-30 |
| AU2009299793B2 (en) | 2016-03-10 |
| SI2352763T1 (sl) | 2016-07-29 |
| US20160264671A1 (en) | 2016-09-15 |
| HUE027499T2 (en) | 2016-10-28 |
| US9260522B2 (en) | 2016-02-16 |
| PL2352763T3 (pl) | 2016-10-31 |
| SMT201600232B (it) | 2016-08-31 |
| US20110262439A1 (en) | 2011-10-27 |
| WO2010037837A3 (en) | 2010-07-22 |
| ES2582603T5 (es) | 2022-12-02 |
| CA2738566A1 (en) | 2010-04-08 |
| DK2352763T3 (en) | 2016-06-27 |
| SI2352763T2 (sl) | 2022-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160857T4 (hr) | Bispecifična jednolančana protutijela, specifična za visokomolekulske ciljne antigene | |
| CN111518214B (zh) | 靶向cldn18.2的双特异性抗体及其制备方法和应用 | |
| JP2019525738A5 (hr) | ||
| JP2023053239A (ja) | 長寿命ポリペプチド結合分子 | |
| HRP20191697T1 (hr) | Vezujuće molekule za bcma i cd3 | |
| CA2522586C (en) | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders | |
| HRP20201004T1 (hr) | Modificirani polipeptidi za skelete bispecifičnog protutijela | |
| CN103068846B9 (zh) | 包含二硫键稳定性Fv片段的双特异性抗体 | |
| RU2017110044A (ru) | Антитела и химерные антигенные рецепторы, специфичные к cd19 | |
| FI2155783T4 (fi) | Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni | |
| HRP20190756T1 (hr) | Cd3-vezujuće molekule sposobne za vezanje za humani i nehumani cd3 | |
| JP2020508655A5 (hr) | ||
| RU2019126655A (ru) | Нуклеиновые кислоты, кодирующие химерные рецепторы, полипептидные химерные рецепторы, кодируемые ими, векторы экспрессии, содержащие их, выделенные клетки-хозяева, содержащие их, композиции, содержащие выделенные клетки-хозяева, а также способы получения выделенных клеток-хозяев in vitro, способы выбора нуклеиновых кислот, кодирующих химерные рецепторы, in vitro и способы проведения клеточной иммунотерапии у субъекта, имеющего опухоль | |
| JP2010512324A5 (hr) | ||
| JP2017522892A5 (hr) | ||
| JP2018504890A5 (hr) | ||
| RU2020120613A (ru) | Антитела, нацеленные на рецептор, связанный с g-белками, и способы их применения | |
| JP2014158485A5 (hr) | ||
| JP2010502183A5 (hr) | ||
| JP2010511397A5 (hr) | ||
| RU2015111708A (ru) | Способ получения и отбора молекул, включающих по меньшей мере две различные группировки и их применение | |
| JP2016533763A5 (ja) | ヒトｐｄ−１に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物 | |
| RU2015100230A (ru) | Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения | |
| RU2016106577A (ru) | САЙТЫ АНТИТЕЛ, СПЕЦИФИЧНО СВЯЗЫВАЮЩИЕ EGFRvIII | |
| JP2013535191A5 (hr) |